Correction: CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells (Cell Death & Disease, (2016), 7, 4, (e2209), 10.1038/cddis.2016.102);CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells

Cell Death and Disease

Volumn 7, Issue 4, 2016, Pages

  Drachsler, M ^a   Kleber, S ^a   Mateos, A ^a   Volk, K ^a   Mohr, N ^a   Chen, S ^a   Cirovic, B ^b   Tuttenberg J ^c   Gieffers, C ^d   Sykora, J ^d   Wirtz, C R ^e   Mueller, W ^f   Synowitz, M ^g,h   Martin Villalba, A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Klinikum Idar Oberstein   (Germany)

^d APOGENIX GMBH   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Department of Neurosurgery ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNERCEPT; FAS LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; ALKYLATING AGENT; DACARBAZINE; DRUG COMBINATION; FAS ANTIGEN; FAS PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STEM CELL; CLINICAL FEATURE; CONTROLLED STUDY; DEATH DOMAIN; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; PATHOLOGY; PRIMARY CELL CULTURE; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DACARBAZINE; DRUG COMBINATIONS; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOGLOBULIN G; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PRIMARY CELL CULTURE; PROGNOSIS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; SURVIVAL ANALYSIS;

EID: 84990251541     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-020-2698-3     Document Type: Erratum

References (45)

1. Chen J, Li Y, Yu T-S, McKay RM, Burns DK, Kernie SG et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522–526.
2. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012; 488: 527–530.
3. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730–735.
4. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.
5. Scheel C, Eaton EN, SH-J Li, Chaffer CL, Reinhardt F, Kah K-J et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145: 926–940.
6. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820–13825.
7. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA et al. TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010; 18: 655–668.
8. Bazzoli E, Pulvirenti T, Oberstadt MC, Perna F, Wee B, Schultz N et al. MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell 2012; 11: 836–844.
9. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 2012; 22: 765–780.
10. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 2013; 23: 238–248.
11. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, MacSwords J et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421–432.
12. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396–401.
13. Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440–452.
14. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010–4015.
15. Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S et al. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One 2009; 4: e5498.
16. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243.
17. Trauth BC, Klas C, Peters AM, Matzku S, Möller P, Falk W et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301–305.
18. Martin-Villalba A, Llorens-Bobadilla E, Wollny D. CD95 in cancer: tool or target? Trends Mol Med 2013; 19: 329–335.
19. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23: 3175–3185.
20. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008; 13: 235–248.
21. Chen L, Park S-M, Tumanov AV, Hau A, Sawada K, Feig C et al. CD95 promotes tumour growth. Nature 2010; 465: 492–496.
22. Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B et al. Death induced by CD95 or CD95 ligand elimination. Cell Rep 2014; 7: 208–222.
23. Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aykut B, Mateos A et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death Differ 2015; 22: 1192–1202.
24. Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak A, Hau A, Liu X et al. CD95 and CD95L promote and protect cancer stem cells. Nat Commun 2014; 5: 5238.
25. Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009; 5: 178–190.
26. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061–1068.
27. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98–110.
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.
29. Beckervordersandforth R, Tripathi P, Ninkovic J, Bayam E, Lepier A, Stempfhuber B et al. In vivo fate mapping and expression analysis reveals molecular hallmarks of prospectively isolated adult neural stem cells. Cell Stem Cell 2010; 7: 744–758.
30. Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ et al. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer 2011; 11: 529.
31. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012; 338: 1080–1084.
32. Lei L, Sonabend AM, Guarnieri P, Soderquist C, Ludwig T, Rosenfeld S et al. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One 2011; 6: e20041.
33. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010; 32: 240–252.
34. Lee J, Sayed N, Hunter A, Au KF, Wong WH, Mocarski ES et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 2012; 151: 547–558.
35. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314–322.
36. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349–361.
37. Beck B, Lapouge G, Rorive S, Drogat B, Desaedelaere K, Delafaille S et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 2015; 16: 67–79.
38. Henderson V, Smith B, Burton LJ, Randle D, Morris M, Odero-Marah VA. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Cell Adh Migr 2015; 9: 255–264.
39. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639–644.
40. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582–589.
41. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313–323.
42. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015; 527: 472–476.
43. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527: 525–530.
44. Tuettenberg J, Seiz M, Debatin K-M, Hollburg W, Staden von M, Thiemann M et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol 2012; 13: 93–100.
45. Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 2014; 20: 6304–6313.